Cash and cash equivalents were $260.1M as of March 31, 2025, vs. $165.1M as of December 31, 2024. An additional $140.4M net cash raised in Q1 2025. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said CEO Kabir Nath. “Our continued progress reinforces Compass’ leadership in psychedelic therapy development, which we believe represents the next generation of mental health therapeutic options and can lead to significant value creation.”
Easter Sale - 70% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPS:
- Compass Pathways enters strategic collaboration with HealthPort
- Psychedelic: Clearmind completes clinical site initiations for AUD trial
- Compass Pathways completes dosing in Part A of Phase 3 psilocybin trial
- COMPASS Pathways Amends Executive Employment Agreements
- Psychedelic: Exclusive talk with retreat provider ONE Retreats